Open Monoclocal Technology Acquired By Ligand For $178M
Palo Alto-based OMT (Open Monoclonal Technology), a developer of genetic engineering technology to allow animals to create human, therapeutic antibodies, has been acquired by Ligand in a $178M deal. Ligand said it will pay $92.6M in cash and $85.4M in Ligand common stock for OMT. Ligand will also hire Roland Buelow, founder of OMT, as Vice President of Antibody Technologies. OMT currently says its partners include Amgen, ARMO, Celgene, Five Prime, Genmab, HanAll, Janssen, Merck KGaA, Pfizer, Seattle Genetics, Symphogen, along with others.
posted on Thursday, December 17, 2015
Related companies:
OPEN AIR PUBLISHING INC.
Related stories:
> Crystal Bioscience Acquired By Ligand For Up To $30.5M
> Dune Networks Acquired by Broadcom For $178M
> Virtual PBX Acquires Open Communication Systems
> Ma.gnolia Goes Open source
> Cleantech Investments Grow 18 Percent In Q1
silicontap.com Home